Stanford-StartX Fund contributed to a $12m round for catheter monitor developer CloudCath, whose clinical advisory chairman hails from Stanford University.
US-based remote catheter monitoring technology supplier CloudCath completed a $12m series A round on Thursday backed by Stanford-StartX Fund, the Stanford University-aligned venture fund.
The round was led by Capital Integral, with contributions from FundRx, Capital Partnership, Coconut Tree Investments and unnamed strategic investors and individuals.
Founded in 2019, CloudCath has devised a technology that helps clinicians monitor at-home patients undergoing peritoneal dialysis, where the body’s abdomen lining is infused with dialysate fluids to restore the ideal balance of ions in the blood – a state termed homeostasis.
The system deploys data analytics to monitor fluid parameters in real-time as they enter the patient, automatically flagging up any deviations to ensure more rapid treatment of infections and other complications.
At-home dialysis was one of two treatments, along with kidney transplantation, recommended for most new patients suffering end-stage renal disease, where kidneys lose much of their functional capacity, in a US government order issued in July 2019.
The funding will help commercialise CloudCath’s platform and progress the development of other infectious disease management products based on the same underlying technology.
The chairman of the CloudCath clinical advisory board is Glenn Chertow, chief of the Division of Nephrology at Stanford University’s School of Medicine.
Chertow said: “Studies have shown that home-based kidney care generally improves outcomes, improves the patient experience and provides a much better value to dialysis care providers.
“But many patients lack the confidence to perform dialysis at home, in part due to the lack of monitoring and the disconnect between the home environment and the care teams. Moreover, they fear an infection that may lead to pain and require hospitalisation.”
CloudCath’s existing investors include angel group HealthTech Capital, and the company participated in the summer 2018 cohort of the StartX Med accelerator.
A regulatory filing describes the business as an offshoot of FundRx’s Master Fund I, stating that it received $130,000 for its initial expenses in December 2019.
– Feature image courtesy of CloudCath
